Acute Cardiovascular Effects of the α2-Adrenoceptor Antagonist, Idazoxan, in Rats: Influence of the Basal Sympathetic Tone
- 1 January 2000
- journal article
- Published by Wolters Kluwer Health in Journal of Cardiovascular Pharmacology
- Vol. 35 (1) , 156-163
- https://doi.org/10.1097/00005344-200001000-00021
Abstract
Intravenous administration of the alpha2-adrenoceptor antagonist, idazoxan, elicits variable cardiovascular effects, depending on experimental conditions. In this study, the effects of idazoxan were investigated in rats with high, low, or no basal sympathetic tone. In a group of conscious Sprague-Dawley rats (n = 9), mean arterial pressure (MAP), heart rate (HR), and renal sympathetic nervous activity (RSNA) were recorded. Idazoxan (250 microg/kg, i.v.) induced a transient decrease in MAP (-12+/-3 mm Hg) that was accompanied by increases in HR (49+/-14 beats/min) and RSNA (53+/-14%). In six of nine rats, a light pentobarbitone anesthesia was given. Basal RSNA was decreased (6.0+/-1.3 microV from 12.8+/-4.1 microV; p<0.05), and the depressor effect of idazoxan was reversed to a pressor effect (21+/-6 mm Hg) associated with bradycardia (-16+/-8 beats/min) and sympathoinhibition (-56+/-15%). In eight conscious intact rats, idazoxan (250 microg/kg, i.v.) attenuated by approximately 40% the pressor response to the selective alpha1-adrenoceptor agonist, cirazoline (0.5 microg/kg, i.v.). In three groups of six to seven ganglion-blocked (chlorisondamine, 2.5 mg/kg, i.v.) conscious rats, idazoxan dose-dependently increased mean arterial pressure (MAP: 39+/-2, 55+/-3, and 69+/-4 mm Hg at 125, 250, and 500 microg/kg, i.v., respectively) with minimal changes in HR. In contrast, the noradrenaline-releasing agent, tyramine (62.5, 125, and 250 microg/kg, i.v.), dose-dependently increased both MAP and HR. The alpha1-adrenoceptor antagonist, prazosin (1 mg/kg, i.v.; n = 8) blunted by approximately 70% (p<0.01) the pressor effect of 250 microg/kg idazoxan. It is concluded that in rats with high sympathetic tone, idazoxan has depressor effects, most likely related to its peripheral alpha-adrenoceptor antagonist properties. In rats with low or no sympathetic tone, idazoxan induced pressor responses mainly secondary to its partial agonist activity at vascular postjunctional alpha1-adrenoceptors.Keywords
This publication has 18 references indexed in Scilit:
- A comparative study of the reversal by different α2‐adrenoceptor antagonists of the central sympatho‐inhibitory effect of clonidineBritish Journal of Pharmacology, 1996
- Sympathoinhibitory effects of rilmenidine may be mediated by sites located below the brainstemBritish Journal of Pharmacology, 1992
- BARORECEPTOR RESETTING AND OTHER DETERMINANTS OF BAROREFLEX PROPERTIES IN HYPERTENSIONClinical and Experimental Pharmacology and Physiology, 1989
- Effect of CH-38083, a selective antagonist of alpha2-adrenoceptors, on renal sympathetic functionNeuropharmacology, 1989
- Idazoxan (RX 781094) selectively antagonizes α2-adrenoceptors on rat central neuronsEuropean Journal of Pharmacology, 1984
- Pharmacokinetics of Pentobarbital, Quinidine, Lidocaine, and Theophylline in the Thermally Injured RatJournal of Pharmaceutical Sciences, 1984
- Comparison of the ?-adrenoceptor antagonist profiles of idazoxan (RX 781094), yohimbine, rauwolscine and corynanthineNaunyn-Schmiedebergs Archiv für experimentelle Pathologie und Pharmakologie, 1984
- α1-Adrenoceptor agonist activity of α2-adrenoceptor antagonists in the pithed rat preparationBritish Journal of Pharmacology, 1983
- Studies on RX 781094: a selective, potent and specific antagonist of α2‐adrenoceptorsBritish Journal of Pharmacology, 1983
- RX781094, a new potent ?2 adrenoceptor antagonistNaunyn-Schmiedebergs Archiv für experimentelle Pathologie und Pharmakologie, 1983